Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigenics COO Trades in Frequent Flier Life for Proteomics in Paris


The new COO at Hybrigenics has made a number of jumps in her career. Starting out in research, she headed to development and later moved again when an offer came along and piqued her curiosity about working on the business side. Now, she’s making the shift from big pharma to a small proteomics company. “It is indeed a major new challenge in my career,” says Anne-Fabienne Weitsch.

Formerly senior director of licensing and business development at Johnson & Johnson, Weitsch got first-hand experience navigating the biotech world (and airports: “I was living in Belgium and spending 40 percent of my time in the US,” she says). After eight years at J&J and previous time in R&D at her native Switzerland’s CIBA, she decided she was ready to move to the smaller realm of proteomics and functional proteomics at Paris-based Hybrigenics.

Since she’s already well-versed in the field, “the real learning curve will be the business operations of the biotech company,” she says. “My role will be very operational, more turned toward internal [issues].” That means less traveling, but hey, it’s Paris.

— Meredith Salisbury

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.